gdc
PSSGuide_2021
Cholangiocarcinoma

Drugs for Cholangiocarcinoma (Bile Duct Cancer)

Find financial assistance programs available for cholangiocarcinoma drugs.

Pemazyre (pemigatinib) Tablets

Drug company: Incyte
855-452-5234

Pemazyre is a kinase inhibitor used for the treatment of adults with previously treated, unresectable (can’t be removed by surgery) locally advanced or metastatic cholangiocarcinoma, a type of bile duct cancer, that is associated with an FGFR2 gene fusion or other rearrangements, as detected by an FDA-approved test.

IncyteCARES offers 3 financial assistance programs for patients who have been prescribed Pemazyre:

Pemazyre Copay/Coinsurance Program

Eligible patients who have commercial or private insurance can receive Pemazyre for as little as $0 copay, with a maximum savings benefit of $9,000 per claim and $25,000 per year. Patients who have government insurance are not eligible for this program.

Pemazyre Patient Assistance Program

Eligible patients who have no insurance or have insurance that does not cover the cost of Pemazyre can receive Pemazyre for free if they meet the household and size and annual income criteria, including earning less than $125,000 per year, or less than 600% of the federal poverty level.

Pemazyre Temporary Access Program

Eligible patients who have commercial or private insurance and who experience a delay in coverage may receive a free 30-day supply of Pemazyre by submitting proof of their insurance claim verifying the delay.

Tibsovo (ivosidenib) Tablets

Drug company: Servier Pharmaceuticals
844-409-1141

Tibsovo is an IDH1 inhibitor used for the treatment of adults with previously treated, locally advanced or metastatic cholangiocarcinoma and IDH1 mutation, as detected by an FDA-approved test.

Servier Pharmaceuticals, through ServierOne, offers 4 financial assistance programs for patients using Tibsovo:

Tibsovo Co-Pay Program

Qualified patients who have private insurance pay no more than a $25 copay per prescription of Tibsovo through this program, with a maximum annual benefit of $25,000.

Patient Assistance Program

Uninsured or underinsured patients who meet specified financial and eligibility requirements may qualify for assistance through this program.

QuickStart Program

To qualify for this program, patients must have private insurance coverage that has been delayed by 5 business days or more and meet the specified eligibility requirements.

Coverage Interruption Program

To qualify for this program, patients must reside in the United States and must be currently taking Tibsovo, and have at least 1 previous prescription dispensed with a private insurance.

Truseltiq (infigratinib) Capsules

Drug company: QED Therapeutics
888-552-7434

Truseltiq is a tyrosine kinase inhibitor used for the treatment of adults with previously treated, unresectable (can’t be removed by surgery), locally advanced or metastatic cholangiocarcinoma and an FGFR2 fusion or other rearrangement, as detected by an FDA-approved test.

QED Therapeutics, through ForgingBridges, offers 2 financial assistance programs for patients using Truseltiq:

Truseltiq Copay Assistance Program

Qualified patients with commercial insurance may pay as little as $0 out-of-pocket copay costs per prescription of Truseltiq, for a maximum annual benefit of $40,000.

Truseltiq Patient Assistance Program

Through this program, qualified patients who are uninsured or underinsured may receive Truseltiq at no cost.

Table. Drugs Prescribed for Cervical Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services


    Drug name (generic name)
  • Truseltiq (infigratinib) Capsules
  • Drug company
  • QED Therapeutics
  • Indication
  • Treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and an FGFR2 fusion or other rearrangement
  • Patient support services
  • Truseltiq Copay Assistance Program
    888-552-7434

    Truseltiq Patient Assistance Program
    888-552-7434

Share this:

Last modified: March 21, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest